Firn-M

Firn M is a Russian biotechnology company founded in 1989, specializing in the development and manufacture of recombinant interferon-based pharmaceuticals. The company is best known for its Grippferon line of products, which utilize interferon alfa-2b for the prevention and treatment of influenza and other acute respiratory viral infections. Firn M's portfolio includes a variety of combination therapies that pair interferon with antiviral, antihistamine, or antifungal agents to treat conditions such as viral conjunctivitis (Oftalmoferon), herpes (Gerpferon), and allergic rhinitis (Allergoferon). Headquartered in Moscow, the company maintains its own R&D and manufacturing facilities and holds numerous patents for its original drug formulations. Firn M continues to expand its pipeline with over 30 new preparations under development, focusing on enhancing the efficacy and delivery of interferon-based treatments.